The worldwide Gastroesophageal Reflux Disease (GERD) therapeutics market is anticipated to reach USD 4.34 billion by 2025. Demand for acid reducing drugs for the treatment of GERD is a key demand driver. Prevalence of acid reflux disorders, characterized by chronic heartburn, has increased by 50% over the past few years. This disrupts the wellbeing and quality of lives of the patients. With its high incidence, GERD also takes its toll on global economy & healthcare system.
The global Gastroesophageal Reflux Disease (GERD) therapeutics market is categorized as per drug types and regions. On the basis of drugs, the segments are antacids, pro-kinetic agents, Proton Pump Inhibitors (PPIs), and H2 receptor blockers. Antacids may continue dominating the global market in terms of revenue share during the forecast period. Cost-effectiveness & better customer accessibility make them a common first-aid treatment for acid reflux. Upward trend of self-medication for heartburn is accountable for propelled sales of over-the-counter (OTC) antacids.
PPIs emerged as the second largest segment in 2016. They are the most commonly prescribed acid reflux medications.
In-depth research report on global Gastroesophageal Reflux Disease (GERD) therapeutics market - http://www.grandviewresearch.com/industry-analysis/gastroesophageal-reflux-disease-gerd-therapeutics-market
On the basis of geographies, the market segments are Middle East & Africa (MEA), Latin America, North America, Asia-Pacific (APAC), and Europe. North America accounted for the biggest share in terms of volume in 2016. Each year, In the U.S. more than 80 million people are diagnosed with GERD symptoms, out of which, 25 million people suffer from acid reflux or heartburn on a daily basis and 60 million people on a monthly basis.
Factors driving this dominance are availability of OTC generic drugs and rising number of heartburn patients. Furthermore, the U.S. has witnessed a steep rise in the cases of Gastroesophageal Reflux Disease. Around 18 % of American population will age 65 and above by 2025. Elderly population is at high risk of developing acid reflux & heartburn. This may boost the regional growth of the market in the years to come.
On the other hand, APAC is expected to witness the fastest growth during the next few years. Growth in geriatric population, high-fat diet, obesity, and other risk factors may drive regional growth. Developing nations like China & India are adopting self-medication trend on account of affordability & availability of OTC medications.
Top companies operating in the worldwide Gastroesophageal Reflux Disease (GERD) therapeutics market are Johnson & Johnson Services, Inc.; Eisai Co., Ltd.; AstraZeneca PLC; Takeda Pharmaceutical Co., Ltd.; and GlaxoSmithKline PLC. Majority of market participants focus on developing novel generic molecules as the key growth strategy. High number of generic companies may launch copycat drugs in place of blockbuster GERD medications. This can help them attain larger market share.
Torax has developed an anti-reflux device for GERD treatment. It is known as LINX Reflux Management System. This small implantable band is made of interlocked titanium beads that have magnetic cores. These magnetically charged beads improve the natural barrier function of esophageal sphincter and avoid reflux. The device is implanted with the help of a standard minimally invasive laparoscopy. It also helps the GERD patients who continue to have chronic GERD symptoms in spite of proper treatment.